Recent Updates
Recently added Catalysts
DTIL Positive Sentiment Score: 70/100

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: Precision BioSciences has announced the approval of an inducement award of 7,094 restricted stock units (RSUs) to a new employee. This decision was made by the Compensation Committee of the Board of Directors on April 20, 2026. The company continues to utilize its ARCUS® platform for developing in vivo gene editing therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is expanding its team with new hires.
  • The grant of RSUs indicates a commitment to attracting talent.
  • The company is focused on developing innovative gene editing therapies.

Full Press Release Details

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on April 20, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award of 7,094 restricted stock units (“RSUs”) to a new employee under the Precision BioSciences, Inc. 2021 Employment Inducemen

Frequently Asked Questions

What are the inducement awards granted by Precision BioSciences?

Precision BioSciences granted 7,094 restricted stock units (RSUs) to a new employee.

When were the inducement awards approved?

The inducement awards were approved on April 20, 2026.

What is the purpose of the RSUs granted?

The RSUs are part of an effort to attract and retain talent at Precision BioSciences.

What platform does Precision BioSciences use for gene editing?

Precision BioSciences utilizes its proprietary ARCUS® platform for gene editing therapies.

Last updated: Apr 24, 2026